Navigation Links
Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatism's Congress
Date:6/8/2011

NEW YORK, June 8, 2011 /PRNewswire/ -- One of the major annual rheumatology conferences, the European League Against Rheumatism's Congress (EULAR), was held May 25-28 in London.  Citeline, Inc., reviewed the trends and highlights from clinical trial results reported at EULAR, noting that approved biologics in rheumatoid arthritis dominated the program, comprising roughly 25% of clinical trial abstracts presented.  

Updates from long-term trials for approved biologics in RA—including adalimumab, etanercept, abatacept, rituximab and tocilizumab—provided further evidence of sustained clinical efficacy by standard measures, but also extended to reductions in joint damage (by radiographic and MRI methodologies), remission induction and effective treatment of early disease.  Of these approved biologics, tocilizumab trial results were the most numerous, and included several reports of treatment impact on serum lipid levels and other cardiovascular-related outcomes.  

Citeline's Senior Analyst in Autoimmune/Inflammation, Claire Herman, noted that the industry-wide interest in personalized medicine was evident at EULAR, with an array of abstracts presenting results from studies aimed at identifying biomarkers and pharmacogenomic markers as predictors of response to specific approved biologics. "This research is indicative of companies' focus on carving out individual niches within this highly competitive chronic disease arena," remarks Ms. Herman.  

Additionally, a number of these approved drugs' sponsors continue to focus on life-cycle management and expanded labeling, as evidenced by abstracts reporting results from trials of the subcutaneous formulation of abatacept (ALLOW and ACQUIRE), pivotal trials for Japanese approval of golimumab for RA, tocilizumab juvenile RA studies (TENDER), and rituximab combination therapies results. Trends in Trials for Approved Biologic Therapies in Rheumatoid ArthritisNumber of ab
'/>"/>

SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... , May 22, 2015 The leading ... $13 billion global cardiac rhythm management device market ... found that Medtronic, St. Jude Medical, Boston Scientific ... of this market segment. The healthcare market research ... , uses 2015 as a base year, providing ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4
... /PRNewswire-Asia/ -- Recently, Wang Qiao, the eight-year program student ... tutored under Yan Lynan, went to San Francisco to ... meeting with the director of his department, Mr. Li ... The theme of the meeting is "The Pros ...
...  Marken announced today that it has opened its first ... service operations and offer local service to its customers ... operates in the country through its partners, managing thousands ... country.  This new office has been created recognizing that ...
Cached Medicine Technology:Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States 2Marken Opens Branch Office In Seoul, South Korea 2
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... A live auction will be held to sell over ... other medical facilities around the United States. Various types ... anesthesia, exam and much more. , The live auction ... starting at 9:00am CDT each day. The equipment is at ... Park, IL 60160. Anyone can participate in the auction ...
(Date:5/22/2015)... The world is at a ... intersecting to create new opportunities for leadership in ... at WesternU's 34th annual Commencement Exercises said Wednesday, ... a former San Francisco mayor and likely 2018 ... graduation ceremony for WesternU's colleges of Allied Health ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... , SUNDAY, May 13 (HealthDay News) -- A new type ... people who have lost their vision due to degenerative eye ... research with rats. The system uses tiny solar panel-like ... a specially designed pair of goggles equipped with a miniature ...
... new study has found that, contrary to current thinking, taking ... a person,s risk of developing colorectal cancer. Published early online ... Cancer Society, the study also revealed that even long-term use ... cancer risk. In recent years, researchers have thought that ...
... , THURSDAY, May 10 (HealthDay News) -- An advisory panel ... approval of the weight-loss medication lorcaserin, even though concerns remain ... give the nod to the drug, lorcaserin would become the ... decade. The FDA is not bound to follow the advice ...
... is the leading cause of death among children under 5, ... Johns Hopkins Bloomberg School of Public Health. They examined the ... found that 64 percent were attributable to infectious causes and ... the May issue of the Lancet , suggest a ...
... who are making a big difference in the highly ... two early-stage discovery awards from Grand Challenges Explorations, an ... The global health projects will focus on creating ... for low-cost, in-home diagnoses. The prestigious awards ...
... reduced mobility now have access to specialized exercise equipment ... between the University of Alberta and the Spinal Cord ... functional electrical stimulation (FES) rehabilitation therapy machines are now ... the Faculty of Physical Education and Recreation at the ...
Cached Medicine News:Health News:In Rat Study, Eye Device Shows Promise for Restoring Sight 2Health News:Blood pressure drugs don't protect against colorectal cancer 2Health News:FDA Panel Gives Blessing to New Weight-Loss Drug 2Health News:Pneumonia and preterm birth complications are the leading causes of childhood death 2Health News:2 Grand Challenges Explorations grants for global health 2Health News:Partnership provides inclusive workout 2Health News:Partnership provides inclusive workout 3
... The assay is a direct competitive ... in human serum or plasma. A specific ... it available for antibody binding. Estradiol then ... to fluorescein isothiocyanate (FITC) and alkaline phosphatase ...
... the most potent, naturally secreted estrogen and ... ovary [1]. In the ovary, estradiol is ... a less potent estrogen derived from androstenedione. ... body tissues. In men, small amounts of ...
... troponin I (cTnI) has been useful in ... Emergency Departments (ED) with chest pain. 18-20 ... when blood levels of sensitive and specific ... isoenzyme of creatine kinase (CK-MB), and myoglobin, ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
Medicine Products: